 |
|
Dartmouth and GlycoFi report full humanization of therapeutic proteins from yeast
September 08, 2006Research advances drug development efforts
HANOVER, NH - Researchers at Dartmouth's Thayer School of Engineering, Dartmouth Medical School, and the biotechnology firm GlycoFi, Inc., report a significant advance in the production of therapeutic proteins. Reported in the Sept. 8 issue of the journal Science, the Dartmouth/GlycoFi team announced the complete humanization of the glycosylation pathway in the yeast Pichia Pastoris.
"We've successfully completed one of the most complex cellular engineering endeavors undertaken to date," said Tillman Gerngross, chief scientific officer of GlycoFi and professor of engineering at Dartmouth.
Protein-based therapies represent more than half of all the drugs currently in development, and they have to be manufactured by living cells, which are genetically engineered to produce a given protein of interest. However, most of these proteins require the attachment of sugar structures, a process known as glycosylation, to attain full biological function. To date, this has required the expression of such proteins in mammalian cells that have the ability to attach human-like sugar structures.
This new finding replicates all the steps of human glycosylation within a yeast cell, eliminating the need for mammalian cells. Plus, report the researchers, the technology offers numerous advantages over the conventional use of mammalian cell cultures, namely reduced risk of contamination by pathogens and infectious agents along with improved drug performance and manufacturing efficiency.
"Humanizing glycosylation in yeast was a tour de force of genetic engineering, requiring the knockout of four yeast genes and the introduction of over 14 heterologous genes," said Stephen Hamilton, the lead author on the study and a senior scientist at GlycoFi.
The study details the genetic engineering of the yeast Pichia pastoris to secrete human glycoproteins with fully complex, terminally sialyated N-glycans. The researchers demonstrated the effectiveness of this approach when the glycoengineered yeast strain was used to produce functional erythropoietin, a protein widely used in the treatment of anemia, and considered to be the most successful biotech drug to date.
Gerngross noted that the GlycoFi/Dartmouth research team previously demonstrated the importance of glycosylation structures on other commercially relevant therapeutic proteins such as antibodies (published in Nature Biotechnology earlier this year). Like with most glycoproteins the researchers were able to show that, by controlling glycosylation, they could significantly improve an antibodies ability to kill cancer cells.
"By engineering yeast to perform the final and most complex step of human glycosylation, we will be able to conduct far more extensive structure-function investigations on a much wider range of therapeutic protein targets," Gerngross said.
Dartmouth College
Protein-based therapies represent more than half of all the drugs currently in development, and they have to be manufactured by living cells, which are genetically engineered to produce a given protein of interest. However, most of these proteins require the attachment of sugar structures, a process known as glycosylation, to attain full biological function. To date, this has required the expression of such proteins in mammalian cells that have the ability to attach human-like sugar structures.
This new finding replicates all the steps of human glycosylation within a yeast cell, eliminating the need for mammalian cells. Plus, report the researchers, the technology offers numerous advantages over the conventional use of mammalian cell cultures, namely reduced risk of contamination by pathogens and infectious agents along with improved drug performance and manufacturing efficiency.
"Humanizing glycosylation in yeast was a tour de force of genetic engineering, requiring the knockout of four yeast genes and the introduction of over 14 heterologous genes," said Stephen Hamilton, the lead author on the study and a senior scientist at GlycoFi.
The study details the genetic engineering of the yeast Pichia pastoris to secrete human glycoproteins with fully complex, terminally sialyated N-glycans. The researchers demonstrated the effectiveness of this approach when the glycoengineered yeast strain was used to produce functional erythropoietin, a protein widely used in the treatment of anemia, and considered to be the most successful biotech drug to date.
Gerngross noted that the GlycoFi/Dartmouth research team previously demonstrated the importance of glycosylation structures on other commercially relevant therapeutic proteins such as antibodies (published in Nature Biotechnology earlier this year). Like with most glycoproteins the researchers were able to show that, by controlling glycosylation, they could significantly improve an antibodies ability to kill cancer cells.
"By engineering yeast to perform the final and most complex step of human glycosylation, we will be able to conduct far more extensive structure-function investigations on a much wider range of therapeutic protein targets," Gerngross said.
Dartmouth College
Glycosylation Current Events and Glycosylation News RSSResearchers identify individuals at risk for developing colon cancer
A new study identifies a group of individuals at increased risk for developing colon cancer and holds the promise for developing new tailored cancer treatments.
A potential drug for liver carcinoma
Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect.
Connections between diabetes and Alzheimer's disease explored
Modern societies face the increasing burden of age-related diseases, in particular Alzheimer's disease (AD) and type 2 diabetes (T2D).
Researchers Apply Systems Biology and Glycomics to Study Human Inflammatory Diseases
An innovative systems biology approach to understanding the carbohydrate structures in cells is leading to new ways to understand how inflammatory illnesses and cardiovascular disease develop in humans. The work was described in two recent publications by University at Buffalo chemical engineers.
Molecular evolution of influenza A viruses circulated in Fujian Province, China
Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 - 2004 and demonstrated some key codons responsible for antigenic drift. The study is reported in Issue 51 (April, 2008) of the Science in China Series C: Life Science because of its significant impact.
Cell-surface sugar defects may trigger nerve damage in multiple sclerosis patients
Defects on cell-surface sugars may promote the short-term inflammation and long-term neurodegeneration that occurs in the central nervous system of multiple sclerosis patients, according to University of California, Irvine researchers.
New studies show topical glucosamine targets pigment overproduction
Data presented at 2006 American Academy of Dermatology Meeting uses first ever non-invasive imaging system to detect pigment changes, test glucosamine efficacy.
Researchers discover how a high-fat diet causes type 2 diabetes
Howard Hughes Medical Institute researchers have discovered a molecular link between a high-fat, Western-style diet, and the onset of type 2 diabetes.
A new prognostic tool for gastric carcinomas? (and maybe other cancers)
A new way to identify gastric carcinoma patients with high probability of develop a more aggressive form of disease has just been described on the June issue of the journal Glycobiology.
HIV: a sugar shield to evade host defences
In humans, the Aids virus HIV manifests extreme genetic variability. It is particularly virulent, probably because its introduction into populations is recent (2). It has a potential for rapid evolution, at both population and individual scales, owing to a mutation rate among the highest in the living world, and to its recombination capacity. This high evolutionary potential is one of the major obstacles hindering the development of an effective vaccine. Starting from the principle that this mutation-based evolution of the virus is a response to selective pressures exerted by the host immune response (thought to be the dominant evolutionary force) , IRD researchers and their project partners
More Glycosylation Current Events and Glycosylation News Articles
 |
Essentials of Glycobiology, Second Edition by Ajit Varki (Author), Richard D. Cummings (Author), Jeffrey D. Esko (Author), Hudson H. Freeze (Author), Gerald W. Hart (Author), Marilynn E. Etzler (Author) The sugar chains of cells—known collectively as glycans—play a variety of impressive, critical, and often surprising roles in biological systems. Glycobiology is the study of the roles of glycans in the growth and development, function, and survival of an organism. Glyco-related processes, described in vivid detail in the text, have become increasingly significant in many areas of basic research as well as biomedicine and biotechnology. This new edition of Essentials of Glycobiology covers the general principles and describes the structure and biosynthesis, diversity, and function of glycans and their relevance to both normal physiologic processes and human disease. Several new chapters present significant advances that have occurred since the publication of the first edition.... |
 |
Protein Glycosylation by Roslyn M. Bill (Author), Leigh Revers (Author), Iain B.H. Wilson (Author) Protein Glycosylation provides clear, up-to-date, and integrated coverage of key topics in this field. Particular emphasis is placed on the biosynthetic pathways that result in a wide variety of identified protein-bound oligosaccharides. Protein Glycosylation begins with an overview of the chemical structures of mono- and oligosaccharides, to provide a scientific basis for the later chapters. The book includes discussions on the purification, function, and enzyme kinetics of selected glycosidases and glycotransferases, as well as a review of the roles of oligosaccharides in glycoprotein function and the in vivo role of glycoproteins themselves. Finally, the in vitro synthesis of glycoproteins is presented, together with future directions in glycobiology. Protein... |
 |
Cell Engineering: Glycosylation by Mohammed Al-Rubeai (Editor) Univ. of Birmingham, UK. Text provides reviews of the advances in glycans and recombinant proteins. Contains an in-depth assessment of methodology and various approaches for the improvement of glycoprotein production. Written for research students, scientists, industrial biotechnologists, and biochemical engineers. Expanded-outline format. |
 |
Glycosylation: Webster's Timeline History, 1963 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Glycosylation," including when used in literature (e.g. all authors that might have Glycosylation in their name). As such, this book represents the largest compilation of timeline events associated with Glycosylation when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social... |
 |
Protein Glycosylation: Cellular, Biotechnological and Analytical Aspects (GBF Monographs (GBF= Gesellschaft Fur Forschung mbH)) by Harald S. Conradt (Editor) Recombinant DNA technology has enabled the efficient production of large quantities of many biologically important glycoproteins by expression in heterologuous mammalian cell lines. In such quantities these glycoproteins can be used not only in basic research but also - after manufacturing by biotechnological means - for commercial purposes. A recent GBF workshop (Braunschweig, Germany, June 1990) was devoted to this highly significant field. In 39 contributions world-leading experts give a state-of-the-art description ranging from basic research reports to perspectives of practical applications. Pharmaceutical companies involved in the production of clinically important glycoproteins (such as immune-modulators, differentiation factors, hormones and... |
 |
Abnormalities of IgG Glycosylation and Immunological Disorders by D. A. Isenberg (Editor), T. W. Rademacher (Editor) Glycobiology has become the focus of considerable research in recent years as the role of oligosaccharides in both health and disease has come under scrutiny. During this period particular emphasis has been placed on the glycosylation of human immunoglobulins, notably IgG, not least because clear links with a restricted range of human diseases has been established. Abnormalities of IgG Glycosylation and Immunological Disorders uniquely draws together the facts that have emerged to link abnormalities in IgG glycosylation and immunological disease, especially rheumatoid arthritis. It reviews all aspects of immunoglobulin glycosylation abnormalities, including the structural anatomy of glycoproteins; the methods used to analyse them; the clinical aspects of glycobiology in both human disease... |
|
Biochemical and Biophysical Research Communications. Volume 196. Pp. 773-1578. N-Glycosylation of Forms of Angiotensin-Converting Enzyme from Four Mammalian Species. By Ripka et al. 1993 by Ripka et al (Author) | |
|
Altered glycosylation in tumor cells: Proceedings of a Smith-Kline & French-Triton Biosciences-UCLA symposium, held in Keystone, Colorado, April 6-12, ... symposia on molecular and cellular biology) by A.R. Liss (Publisher) | |
|
Disease Related Glycosylation Changes and Biomarker Discovery: Challenges and Possibilities in an Emerging Field - Book Edition of Disease Markers by P.M. Rudd (Author), P.M. Rudd (Editor) Many systems and organizational features of cells are disturbed in disease. These include the pathways that regulate the expression of some 300 proteins involved more or less directly in glycan processing. All cell surface and secreted glycoproteins must travel through the endoplasmic reticulum and the Golgi compartments of the secretory pathway where the enzymatic addition of sugars to proteins and their further processing takes place. Proteins which contain appropriate glycosylation sequons in their primary sequence have the potential to acquire N-(AsnXaaSer/Thr) or O-(Ser/Thr) linked oligosaccharides. The processing of the glycans, carried out by enzymes acting sequentially, generally gives rise to a mixture of glycosylated variants of a glycoprotein, known as glycoforms. The... | |
 |
Advanced Glycation End Products in Nephrology: Meeting on Advanced Glycosylation End-Products in Nephrology: Much More Than Diabetic Nephropathy, Padua, ... Padua, Italy (Contributions to Nephrology) by Italy) Meeting on Advanced Glycosylation End-Products in Nephrology: Much More Than Diabetic Nephropathy (2000 : Padua (Author), Angela D'Angelo (Author), Silvana Favaro (Author), Giovanni Gambaro (Author), Angela D'Angelo (Editor), Silvana Favaro (Editor), Giovanni Gambaro (Editor) The pathological role of advanced glycation end products (AGEs) and of oxidative-carbonylic stress is well known in the context of diabetes. Moreo ver, there is also strong evidence that they play a pivotal role in the pathogenesis of some chronic disorders related to uremia, and namely to cardiovascular complications and dialysis-related amyloidosis. They may even play a crucial role in the loss of function of the peritoneal membrane in patients on peritoneal dialysis, a problem which limits the duration of such a treatment. Written by authoritative European experts, this publication includes contributions on AGEs as related to diabetic nephropathy, hemodialysis and, particularly, peritoneal dialysis. The topics covered range from basic research (such as novel pathogenic pathways... |
| © 2009 BrightSurf.com |